Laura Deming, Founder & Managing Partner of The Longevity Fund

Since I was a kid, I’ve been fascinated by the idea that longevity is a mechanism we can manipulate. I grew up in New Zealand. When I was 12, I moved to the US to take graduate coursework at UCSF before studying at MIT. I’ve worked in the Kenyon, Guarente, Weiss and Firestein labs on a number of topics, including aging and synthetic biology. In 2011, I started Longevity Fund, the first VC firm dedicated to funding high-potential longevity companies. So far, we’ve raised $26M and have backed Unity Biotechnology, Precision Biosciences, Metacrine, Navitor, and Alexo Therapeutics.